Grifols Management

Management criteria checks 2/4

Grifols' CEO is Nacho Abia Buenache, appointed in Apr 2024, has a tenure of less than a year. directly owns 0.014% of the company’s shares, worth $782.21K. The average tenure of the management team and the board of directors is 6.3 years and 8.5 years respectively.

Key information

Nacho Abia Buenache

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.01%
Management average tenure	6.3yrs
Board average tenure	8.5yrs

Recent management updates

Recent updates

Portfolio Manager Diary: Contrast The Information Obtained By The Company Management Before Investing

Jan 03

Grifols Class B: Buy The Recovery In The U.S. Plasma Business

Nov 11

Grifols S.A. goes ex-dividend tomorrow

Oct 29

CEO

Nacho Abia Buenache (55 yo)

less than a year

Tenure

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Thomas Glanzmann	Executive Chairman	18.1yrs	€1.90m	0.029% € 1.7m
Jose Ignacio Abia Buenache	CEO & Director	less than a year	no data	0.014% € 782.2k
Alfredo Guerra	CFO & VP	17.3yrs	no data	no data
Lluis Gomez	Senior Vice President of Strategy & COO Office	no data	no data	no data
Nuria Lapeña	VP of Corporate Treasury	no data	no data	no data
David Bell	Chief Corporate Development	21.3yrs	no data	0.0029% € 168.8k
Maria Teresa-Rioné Llano	Chief Communications Officer	6.3yrs	no data	0.00078% € 44.6k
Camille Alpi	Chief Human Resources & Talent Officer	less than a year	no data	no data
Vicente Blanquer Torre	Chief Quality Officer	31.3yrs	no data	0.0066% € 377.1k
Sergio Adell	President of Commercial Tech Support	5.3yrs	no data	no data
Víctor Grifols Deu	Executive Director	no data	€1.04m	0.0022% € 123.0k
Miguel Montblanch	President of Commercial Operations Support	12.3yrs	no data	no data

6.3yrs

Average Tenure

58.5yo

Average Age

Experienced Management: GRFS's management team is seasoned and experienced (6.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Glanzmann	Executive Chairman	18.1yrs	€1.90m	0.029% € 1.7m
Jose Ignacio Abia Buenache	CEO & Director	less than a year	no data	0.014% € 782.2k
Víctor Grifols Deu	Executive Director	8yrs	€1.04m	0.0022% € 123.0k
Juan Twose Roura	Member of the Advisory Committee	9.3yrs	€380.00k	no data
Raimon Grifols Roura	Vice-Chairman	9yrs	€1.04m	0.0060% € 346.2k
Tomas Daga Gelabert	Independent External Director	24.1yrs	no data	0.045% € 2.6m
Inigo Mardones	Independent Director	9yrs	€150.00k	no data
Carina Szpilka Lázaro	Lead Independent Director	9yrs	€150.00k	0.00022% € 12.6k
James Costos	Independent Director	3.6yrs	€138.00k	no data
Albert Coma-Cros	Proprietary Director	less than a year	no data	0.0097% € 556.2k
Enriqueta Font	Independent Director	5yrs	€125.00k	no data
Montserrat Abellana	Independent Director	1.9yrs	€63.00k	no data

8.5yrs

Average Tenure

59yo

Average Age

Experienced Board: GRFS's board of directors are considered experienced (8.5 years average tenure).

Grifols Management

Management criteria checks 2/4

Key information

Recent management updates

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Announces Management Changes

Recent updates

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols: Q4 Was Positive, Still Too Many Question Marks

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols: I've Read The Short-Seller Report, And I Mostly Disagree

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Grifols inks 15-year deal with Canada for plasma-derived therapies

Grifols: Every Cloud Has A Silver Lining

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols: Long Only

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021

Grifols Takes Another Step in the Fight Against Alzheimer's, Partners with Ace to Open First Ambar® Center in Barcelona

Grifols shares rise after Andorra Development and Investment deal

Grifols Launches Patient Point-Of-Care System for Monitoring Infliximab in Europe

Grifols, S.A. (BME:GRF) acquired remaining 56% stake in GigaGen, Inc. for $80 million

Grifols, S.A. (BME:GRF) acquired 25 U.S. Based Plasma Donation Centers of BPL Plasma, Inc for $370 million.

Grifols, S.A.(BME:GRF.P) dropped from S&P Global BMI Index

Grifols Begins Clinical Trial of A New Treatment That Would Provide Immediate Immunity Against Covid-19

Portfolio Manager Diary: Contrast The Information Obtained By The Company Management Before Investing

Grifols, S.A. Announces Board Appointments

Grifols, S.A. (BME:GRF) completed the acquisition of remaining 52.4% stake in Alkahest, Inc.

Grifols, S.A. Executes Binding Master Joint Venture Agreement with National Service Projects Organization

B. Braun Melsungen AG and Grifols Forms Strategic Alliance to Offer Integrated Solutions for Safe Automated Drug Preparation and Administration

Grifols Class B: Buy The Recovery In The U.S. Plasma Business

Grifols, S.A. (BME:GRF) acquired remaining 49% stake in Goetech LLC for $60.2 million.

Grifols S.A. goes ex-dividend tomorrow

Grifols' anti-SARS-CoV-2 Hyperimmune Globulin Begins Clinical Trial in Patients with Covid-19

Grifols, S.A. (BME:GRF) agreed to acquire 53.4% stake in Green Cross Biotherapeutics Inc. from Green Cross North America Inc. for approximately KRW 190 billion.

Grifols, S.A. to Report Q3, 2020 Results on Nov 05, 2020

Grifols, S.A. (BME:GRF) completed the acquisition of Plasma Fractionation Facility in Montreal and Plasma Collection Centers in US from Green Cross Corporation (KOSE:A006280).

Grifols, S.A. (BME:GRF) agreed to acquire remaining 52.4% stake in Alkahest, Inc. for approximately $150 million.

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age